Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 19/20 | 0.57 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.57 |
| ▸ | PDE4A | P27815 | 14/20 | 0.57 |
| ▸ | PDE4C | Q08493 | 14/20 | 0.57 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.55 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6029798 | 0.99 | PDE4D (0.56) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL6030647 | 0.91 | PDE4B (0.67) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| Hydrochloric Acid SCHEMBL6030790 | 0.90 | PDE4B (0.66) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL5564451 | 0.89 | PDE4B (0.61) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL5564449 | 0.89 | PDE4B (0.61) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL5564455 | 0.89 | PDE4B (0.61) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| Hydrochloric Acid SCHEMBL5559811 | 0.88 | PDE4B (0.60) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| Hydrochloric Acid SCHEMBL5559813 | 0.88 | PDE4B (0.60) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| Hydrochloric Acid SCHEMBL5559817 | 0.88 | PDE4B (0.60) | PDE4DPDE4BPDE4APDE4CPDE3B | |
| SCHEMBL6028769 | 0.88 | PDE4D (0.59) | PDE4DPDE4BPDE4APDE4CPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7022696-B2 | Piperazino-derivatives and their use as PDE4 inhibitor | ALTANA PHARMA AG (DE) | 2006-04-04 | — | — | US | disclosed |
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | ATLANTA PHARMA AG (DE) | 2004-07-08 | — | — | US | disclosed |
| EP-1385838-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-02-04 | — | — | EP | disclosed |
| WO-2002085885-A1 | PIPERAZINO-DERIVATIVES AND THEIR USE AS PDE4 INHIBITOR | ALTANA PHARMA AG (DE) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132721-A1 | Piperazino-derivatives and their use as pde4 inhibitor | PDE4A, PDE4B, PDE3A | PDE4D 4/4885PDE4B 2/4885PDE4A 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.